Fig. 3

Nilotinib decreases LPS-mediated microglial neuroinflammatory responses in a Sod2-dependent manner. a Real-time PCR analysis of Sod2 gene expression in LPS-treated BV2 microglial cells post-treated with nilotinib as shown (n = 6/group). b–e Real-time PCR analysis of relative Sod2, IL-6, IL-1β, and COX-2 mRNA levels in BV2 microglial cells transfected with Sod2 siRNA (30 nM) or control (scramble) siRNA for 24 h and subsequently treated with LPS and nilotinib as shown (n = 8/group). C: control, L: LPS, Nil + L: nilotinib + LPS, *p < 0.05, ***p < 0.001